Sierra Oncology, Inc. – NASDAQ:SRRA
Sierra Oncology stock price today
$54.99
Market closed
Open in about 16 hours
Sierra Oncology stock price monthly change
+0.38%
month
Sierra Oncology stock price quarterly change
+67.14%
quarter
Sierra Oncology stock price yearly change
+182.44%
year
Sierra Oncology key metrics
Market Cap | N/A |
Enterprise value | 884.51M |
P/E | -8.34 |
EV/Sales | N/A |
EV/EBITDA | -8.63 |
Price/Sales | N/A |
Price/Book | 4.40 |
PEG ratio | -1.14 |
EPS | -6.77 |
Revenue | N/A |
EBITDA | -102.40M |
Income | -102.67M |
Revenue Q/Q | N/A |
Revenue Y/Y | -100% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSierra Oncology stock price history
Sierra Oncology stock forecast
Sierra Oncology financial statements
| Jun 2021 | 0 | -20.63M | |
|---|---|---|---|
| Sep 2021 | 0 | -28.64M | |
| Dec 2021 | 0 | -25.46M | |
| Mar 2022 | 0 | -27.92M |
| 2021-11-05 | -1.78 | -2.1 |
|---|---|---|
| 2022-03-10 | -1.54 | -1.67 |
| 2022-05-06 | -1.03 | -1.33 |
| Jun 2021 | 94377000 | 10.11M | 10.71% |
|---|---|---|---|
| Sep 2021 | 104227000 | 9.17M | 8.8% |
| Dec 2021 | 109367000 | 13.36M | 12.22% |
| Mar 2022 | 280000000 | 18.37M | 6.56% |
| Jun 2021 | -17.00M | -40K | 113K |
|---|---|---|---|
| Sep 2021 | -29.74M | 0 | 36.15M |
| Dec 2021 | -15.25M | -32K | 22.95M |
| Mar 2022 | -25.73M | -62K | 195.06M |
Sierra Oncology alternative data
| Aug 2023 | 109 |
|---|---|
| Sep 2023 | 109 |
| Oct 2023 | 109 |
| Nov 2023 | 109 |
| Dec 2023 | 109 |
| Jan 2024 | 109 |
| Feb 2024 | 109 |
| Mar 2024 | 109 |
| Apr 2024 | 109 |
| May 2024 | 109 |
| Jun 2024 | 109 |
| Jul 2024 | 109 |
Sierra Oncology other data
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2021 | 5000 | 0 |
| Nov 2021 | 13500 | 0 |
| Jan 2022 | 1900000 | 7000 |
| Feb 2022 | 350000 | 12000 |
| Mar 2022 | 0 | 5553 |
| Apr 2022 | 0 | 8447 |
| Patent |
|---|
Application Filling date: 13 May 2020 Issue date: 21 Jul 2022 |
Application Filling date: 26 Mar 2020 Issue date: 16 Jun 2022 |
Application Filling date: 28 Aug 2019 Issue date: 23 Dec 2021 |
Application Filling date: 21 Aug 2019 Issue date: 30 Sep 2021 |
Application Filling date: 10 Apr 2018 Issue date: 18 Mar 2021 |
Application Filling date: 26 Feb 2019 Issue date: 24 Dec 2020 |
Application Filling date: 1 Jun 2018 Issue date: 21 May 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2019 3 Mar 2020 | Q4 2019 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Stephen George Dilly M.B.B.S, Ph.D. (1960) Pres, Chief Executive Officer & Director | $778,950 |
| Dr. Barbara J. Klencke M.D. (1957) Chief Medical Officer | $706,250 |
| Dr. Mark M. Kowalski M.D., Ph.D. (1955) Chief of Research & Early Devel. | $629,030 |
-
What's the price of Sierra Oncology stock today?
One share of Sierra Oncology stock can currently be purchased for approximately $54.99.
-
When is Sierra Oncology's next earnings date?
Unfortunately, Sierra Oncology's (SRRA) next earnings date is currently unknown.
-
Does Sierra Oncology pay dividends?
No, Sierra Oncology does not pay dividends.
-
What is Sierra Oncology's stock symbol?
Sierra Oncology, Inc. is traded on the NASDAQ under the ticker symbol "SRRA".
-
What is Sierra Oncology's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Sierra Oncology?
Shares of Sierra Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Sierra Oncology's key executives?
Sierra Oncology's management team includes the following people:
- Dr. Stephen George Dilly M.B.B.S, Ph.D. Pres, Chief Executive Officer & Director(age: 65, pay: $778,950)
- Dr. Barbara J. Klencke M.D. Chief Medical Officer(age: 68, pay: $706,250)
- Dr. Mark M. Kowalski M.D., Ph.D. Chief of Research & Early Devel.(age: 70, pay: $629,030)
-
How many employees does Sierra Oncology have?
As Jul 2024, Sierra Oncology employs 109 workers.
-
When Sierra Oncology went public?
Sierra Oncology, Inc. is publicly traded company for more then 10 years since IPO on 16 Jul 2015.
-
What is Sierra Oncology's official website?
The official website for Sierra Oncology is sierraoncology.com.
-
Where are Sierra Oncology's headquarters?
Sierra Oncology is headquartered at 2150 ? 885 West Georgia Street, Vancouver, BRITISH COLUMBIA.
-
How can i contact Sierra Oncology?
Sierra Oncology's mailing address is 2150 ? 885 West Georgia Street, Vancouver, BRITISH COLUMBIA and company can be reached via phone at +1 604 558 6536.
Sierra Oncology company profile:
Sierra Oncology, Inc.
sierraoncology.comExchange:
NASDAQ
Full time employees:
109
Industry:
Biotechnology
Sector:
Healthcare
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
2150 ? 885 West Georgia Street
Vancouver, BRITISH COLUMBIA 94404
Vancouver, BRITISH COLUMBIA 94404
CIK: 0001290149
ISIN: US82640U4040
CUSIP: 82640U404
